Summary
Blue Cross Blue Shield of North Dakota has revised its commercial prior authorization medical drug policies for drugs including Avlayah, bendamustine, bevacizumab, denosumab, omalizumab, Pluvicto and Sarclisa, with revisions effective November 10, 2026. Several HCPCS changes are effective October 1, 2026, including HCPCS codes J1757, J9066 and Q5173, and J3590 is discontinued for Avlayah, Ponlimsi and denosumab-adet on that date. The updates also add the number of days allowed to the Length of Authorization sections, replace specific contraindications in Universal Criteria with general FDA contraindication language, and add ICD-10 codes including C83.36 and C50.A0 through C50.A2.
Get alerts when payers change rules like this one
We check Blue Cross Blue Shield of North Dakota and other payers every day and email you when a change matches your specialty and state.